Viventures
VC Fund
San Mateo, United States
Viventures is a VC fund in San Mateo focused on Software and Biotechnology. Set up in September 1998, Viventures is a venture capital fund with a presence in the United States (San Mateo) and in Europe (Paris). The Fund was established to provide capital for innovative telecommunications and Internet businesses. Viventures invests in start-ups or expanding businesses with innovative Internet and telecommunicationsstrategies. The Fund provides seed capital and supports these newly founded companies in order to ensure their long-term development in Europe as well as in the United States. Viventures' investors include Vivendi, British Telecom, Mannesmann, Siemens, Nokia and Cisco.
- Total investments:
- 36
- Last investment:
- Lead investor:
- 11%
Last updated:
For AI agents: llms.txt
Industries Viventures invests in
Stages Viventures invests in
Countries Viventures invests in
Round sizes
Round size
- Series A
- $10M–$85M
- Series B
- $7M–$79M
Investment Focus
Industry
- Software 7 (19%)
- Biotechnology 7 (19%)
- E-Commerce 5 (14%)
- Health Care 4 (11%)
- Manufacturing 4 (11%)
Stage
- Series B 8 (22%)
- Funding Round 8 (22%)
- Series A 5 (14%)
- Series C 5 (14%)
- Series D 4 (11%)
Country
- United States 16 (44%)
- China 4 (11%)
- France 3 (8%)
- Germany 2 (6%)
- Switzerland 2 (6%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Biovision Pharma is a biomedical enterprise focusing on the research and development of targeted radiopharmaceuticals (TRT) integrated with visual diagnosis and treatment. | $14.9M / Angel / Aug 10, 2022 | ||
| TriArm Therapeutics is a cell therapy company formed by Panacea Venture with R&D operations in Germany, United States and Greater China region. The company focuses on the research and clinical transformation of CD19 CAR-T product using non-viral gene transfer technology, which greatly reduces the cost and time of cell therapy productpreparation, enabling better tumor therapy outcome. | $60M / Venture - Series Unknown / Sep 27, 2021 | ||
| Tactiva Therapeutics is an Immuno-Oncology Company Utilizing an Innovative Approach to Adoptive Cell Therapy. | $35M / Series A / Dec 03, 2018 | ||
| Found in late 2015 with investment from one of Tencent's Founder. An education one-stop technology platform service company that provide online homestay reservation, post-education service and technology solution that target at parents/students who plan to study in USA and education consultant/company who provide service to theseparents. | $2.9M / Seed / Oct 16, 2018 | ||
| Epic Sciences is a privately held diagnostics company committed to improving cancer management by providing easily accessible and real-time biopsy material to guide personalized medicine. Epic is founded on a powerful platform to identify and characterize rare cells including circulating tumor cells ("CTCs"). Epic is working with anumber of partners including numerous pharmaceutical companies, major cancer centers, the National Cancer Institute, and the National Institutes of Health. | $52M / Series E / Sep 12, 2018 | ||
|
Lehui Technology
|
Zhuhai based Media & Entertainment company. | Seed / Jun 07, 2018 | |
| HiFiBiO is a biotherapeutics company that mobilizes the human immune system to combat disease. It commercializes proprietary single-cell technologies for applications in drug and biomarker discovery and development. It also aspires to benefit patients through open-innovation partnerships with industry and academia. HiFiBiO integrates deep-rootedbiological expertise with its comprehensive single-cell profiling technologies to discover and accelerate a pipeline of antibody drugs to treat cancer and autoimmune disorders.The company was founded in 2013 and is headquartered in Paris, Ille-de-France. | $37.5M / Series B / May 16, 2018 | ||
| Ansun BioPharma is a clinical-stage biopharmaceutical company focused on the development of unique host-directed anti-viral. The company is committed to developing safe and effective immuno-biologic therapies to treat the most vulnerable patients. Its founders were ingenious virologists and molecular biologists who realized that targeting a virusis difficult due to the virus’s ability to mutate and avoid the treatment. This ability to mutate also enables the virus to evade vaccines. So instead of trying to hit a moving target, they developed an innovative new approach to fight respiratory viruses: they targeted the host instead of the virus.The company was founded in 2003 and is headquartered in San Diego, California. | $85M / Series A / May 14, 2018 | ||
| Platelet BioGenesis specializes in the fields of biotechnology, platelets, and drug discovery. They discover a new category in therapeutics. The company is developing technology to produce donor-independent human platelets from human induced pluripotent stem cells. | $10M / Series A / Jun 08, 2017 | ||
| Epic Sciences is a privately held diagnostics company committed to improving cancer management by providing easily accessible and real-time biopsy material to guide personalized medicine. Epic is founded on a powerful platform to identify and characterize rare cells including circulating tumor cells ("CTCs"). Epic is working with anumber of partners including numerous pharmaceutical companies, major cancer centers, the National Cancer Institute, and the National Institutes of Health. | $40M / Series D / Apr 28, 2017 | ||
| See all 36 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Viventures invest in?
Viventures invests primarily in Software, Biotechnology and E-Commerce startups, most often at Series B and Funding Round stage. Most of the 36 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Viventures's check size?
Viventures typically joins rounds of $10M–$85M at Series A and $7M–$79M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Viventures participates in.
When did Viventures last invest?
The most recent investment recorded for Viventures closed in Aug 2022. Shizune tracks 36 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
